$1,318.00
This Market Spotlight report covers the Gout market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Gout market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
8 Non-steroidal anti-inflammatory drugs (NSAIDs)
8 Corticosteroids
8 Colchicine
8 Combination therapy
9 Prevention of chronic gout
10 EPIDEMIOLOGY
13 MARKETED DRUGS
16 PIPELINE DRUGS
22 RECENT EVENTS AND ANALYST OPINION
22 SEL-212 for Gout (September 30, 2020)
24 URC102 for Gout (September 27, 2019)
26 KEY UPCOMING EVENTS
27 PROBABILITY OF SUCCESS
28 LICENSING AND ASSET ACQUISITION DEALS
28 Sobi Pays $100m Upfront For Selecta Gout Drug
28 Eisai Acquires Chinese Rights To Fuji Hyperuricemia Drug
29 REVENUE OPPORTUNITY
30 CLINICAL TRIAL LANDSCAPE
31 Sponsors by status
32 Sponsors by phase
33 Recent events
34 BIBLIOGRAPHY
34 Prescription information
36 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of gout, 2019–28
16 Figure 2: Overview of pipeline drugs for gout in the US
17 Figure 3: Pipeline drugs for gout, by company
17 Figure 4: Pipeline drugs for gout, by drug type
17 Figure 5: Pipeline drugs for gout, by classification
24 Figure 6: SEL-212 for Gout (September 30, 2020): Phase II – COMPARE (vs. Krystexxa)
26 Figure 7: Key upcoming events in gout
27 Figure 8: Probability of success in the arthritis pipeline
30 Figure 9: Clinical trials in gout
30 Figure 10: Top 10 drugs for clinical trials in gout
31 Figure 11: Top 10 companies for clinical trials in gout
31 Figure 12: Trial locations in gout
32 Figure 13: Gout trials status
33 Figure 14: Gout trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of gout, 2019–28
14 Table 2: Marketed drugs for gout
19 Table 3: Pipeline drugs for gout in the US
22 Table 4: SEL-212 for Gout (September 30, 2020)
25 Table 5: URC102 for Gout (September 27, 2019)
29 Table 6: Historical global sales, by drug ($m), 2015–19
29 Table 7: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!